Engineered immune cells take aim at hard-to-treat blood cancers in kids
NCT ID NCT04571138
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment for children and young adults up to age 30 whose leukemia or lymphoma has come back or not responded to standard therapy. The treatment uses the patient's own immune cells (T cells) that are genetically modified in a lab to recognize and attack cancer cells carrying a protein called CD22. The study has two parts: the first checks safety and finds the best dose, and the second measures how well the treatment works. About 42 participants will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital Los Angeles
Los Angeles, California, 90027, United States
-
Riley Hospital for Children
Indianapolis, Indiana, 46202, United States
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can engineered immune cells tackle brain lymphoma?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A simple blood test may reveal hidden infertility risk in young cancer survivors